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Abstract
We have previously demonstrated that interleukin-17A (IL-17) producing Th17 cells are 
significantly elevated in blood and bone marrow (BM) in multiple myeloma (MM) and IL-17A 
promotes MM cell growth via the expression of IL-17 receptor. In this study, we evaluated anti-
human IL-17A human monoclonal antibody (mAb), AIN457 in MM. We observe significant 
inhibition of MM cell growth by AIN457 both in the presence and absence of BM stromal cells 
(BMSC). While IL-17A induces IL-6 production, AIN457 significantly down-regulated IL-6 
production and MM cell-adhesion in MM-BMSC co-culture. AIN-457 also significantly inhibited 
osteoclast cell–differentiation. More importantly, in the SCIDhu model of human myeloma 
administration of AIN-457 weekly for 4 weeks after the first detection of tumor in mice led to a 
significant inhibition of tumor growth and reduced bone damage compared to isotype control 
mice. To understand the mechanism of action of anti-IL-17A mAb, we report here, that MM cells 
express IL-17A. We also observed that IL-17A knock-down inhibited MM cell growth and their 
ability to induce IL-6 production in co-cultures with BMSC. These pre-clinical observations 
suggest efficacy of AIN 457 in myeloma and provide the rationale for its clinical evaluation for 
anti-myeloma effects and for improvement of bone disease.
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Introduction
Bone marrow (BM) micro-environments have been shown to play a critical role in multiple 
myeloma (MM) pathobiology1. Immune cells form an important component of this micro-
environment, and are modulated by the conditions generated in the BM2. We have 
previously reported dysfunctional regulatory T cells3 and an increased number of IL-17A 
expressing T helper (Th17) cells in MM4. These immune abnormalities have been 
considered to favor tumor cell progression, both directly as well as by suppressing anti-MM 
immune responses. These immune changes also induce associated bone disease and 
predispose patients to immune-paresis and associated infectious complications5.
T helper cells play an important role in developing a robust and lasting immune response 
against bacterial, fungal and viral infections as well as against tumor cells. Besides Th1, 
Th26 and Treg cells3,7–8, Th17cells play an important role in immune protection against 
pathogens9–11. Furthermore, Th17 cells participate in mediating immuno-pathological 
manifestations of a number of autoimmune diseases12–15. Interestingly, interactions between 
MM cells and the BM micro-environment lead to a production of a number of cytokines and 
chemokines (TGF-β, IL-6, IL-1β and IL23)1 that skew the T helper cell subset differentiation 
to Th17 cells. The Th17 cells in turn, both directly and via pro-inflammatory cytokines 
produced by them, modulate tumor cell growth, suppress Th1 immune responses4 and affect 
other components of tumor micro-environment, especially osteoid elements as in rheumatoid 
arthritis15–16. Higher proportion of Th17 cells are induced from naïve CD4 T cells in MM 
compared to healthy donors4. Dendritic cells (DC) also induce a higher number of Th17 
cells in BM of MM patients17. Furthermore, serum levels of IL-17 are significantly elevated 
in MM compared to healthy donors and this increase is stage-dependent18–22. IL-17 has also 
been shown to play a critical role in the genesis of bone disease in myeloma by mediating 
osteoclast formation and activation23–24. On the other hand, bisphophonates treatment is 
shown to decrease serum levels of IL-17, thus reducing the bone damage reported in MM25. 
IL-17A induces significant increase in proliferation of MM cell lines and primary cells in 
vitro via IL-17A receptor (IL-17RA)4 expressed on tumor cells and IL-17A pretreatment led 
to the development of significantly larger tumors compared to the control in murine 
xenograft model of MM4. Increased frequency of Th17 cells is also observed in a number of 
other human malignancies including, ovarian, prostate, renal, and pancreatic 
carcinomas26–28. These studies provided the rationale to pre-clinically evaluate the effects of 
anti-IL-17A mAb on MM cell-growth both in vitro and in vivo. The results show that MM 
cell-growth and survival are significantly inhibited by anti-IL-17A mAb both in vitro as well 
as in animal studies. IL-17A is produced by myeloma cells and its suppression affects 
myeloma cell growth indicating a possibility of an autocrine loop.
Materials and Methods
Patient samples
Patient BM samples were collected from newly-diagnosed myeloma patients, and from 
patients without treatment for at least 3 months. These samples were collected after 
informed consent in accordance with the Declaration of Helsinki and approved by the 
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institutional review board (IRB) from Dana-Farber Cancer Institute. Healthy donor bone 
marrow samples were obtained from AllCells (Emeryville, CA).
Myeloma cell-proliferation assays
MM cells (MM1S, KMS-12PE, RPMI 8226, KMS-12BM, OPM-1, OPM-2, INA-6, H929, 
U226, and ARP1), cultured in RPMI 1640 supplemented with 10% FBS and antibiotics for 
three days in the presence of isotype or anti-IL-17A mAb (10 µg/ml, AIN 457, Novartis). 
Proliferation was measured by 3H-thymidine incorporation and MTT assay (Life 
Technologies, Grand Island, NY, USA). Co-culture studies were performed with BMSC in 
the presence of isotype control antibody or AIN 457. IL-6 with or without AIN 457 and its 
antibody with or without IL-17A (R & D Systems, Mineapolis, MN, USA)) were used in co-
culture to determine the growth and proliferation in these assays. Colony forming assays 
were performed using MethoCult agar media (Stem Cell Technologies, Vancouver, BC, 
Canada) in the presence of isotype control antibody or anti-IL-17A mAb for three weeks4.
Measurement of IL-6 production by IL-17A and inhibition by AIN 457 using ELISA assays
BMSC were cultured for three days in the presence or absence of IL-17A (100ng/ml), IL-21, 
IL-22, IL-23, IL-27 and LPS at 10ng/ml concentration. For antibody inhibitory studies, 
BMSC in the presence or absence of MM cell-lines was cultured with isotype control 
antibody, or IL-17A, or anti-IL-17A mAb or in combination with IL-17A + anti-IL-17A 
mAb. For ex-vivo studies, the fetal bone chips with MM cells were incubated in the presence 
of isotype control antibody or anti-IL-17A mAb for 2 days. Myeloma cells were co-cultured 
with BMSC in the presence of IL-17A with or without cell-signaling inhibitors (JAK2, 
STAT3, JNK, MEK, NFkB and PI3 inhibitors at 10µM from Cell Signaling, Danvers, MA, 
USA). IL-6 production was measured by standard ELISA (R&D Systems, Minneapolis, 
MN). The immunohistochemical analysis of myeloma cells in the bones was performed by 
staining them with anti-CD138 antibodies4.
Adhesion Assay
Cell adhesion assay was performed as previously describe29. In brief, serum-starved MM 
cells (5 × 106/mL) were first labeled with calcein AM (Molecular Probes, Eugene, OR) and 
cultured with BMSC in the presence of isotype control antibody or anti-IL-17A mAb. The 
absorbance of each well was measured at 492/520 nm plate reader, as described4.
Osteoclast formation
As described earlier30, osteoclasts (OCs) were differentiated from BMMCs from healthy 
volunteers in 6-well plates. Adherent cells were cultured for 21 days in α-MEM containing 
with (positive control) or without (negative control) 50 ng/mL of macrophage colony-
stimulating factor (M-CSF; R&D Systems, Minneapolis, MN) and RANKL (PeproTech, 
Rocky Hill, NJ, USA) with anti-IL-17A mAb or isotype control antibody at 10µg/ml 
concentration. Cells stained for tartrate-resistant acid phosphatase (TRAP) using an acid-
phosphatase leukocyte staining kit (Sigma Aldrich, St Louis, MO, USAl).
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Myeloma murine Xenograft model
Six- to eight week old male Fox Chase CB-17 severe combined immune-deficient (SCID) 
mice (Charles River Laboratories Intl. Inc., Wilmington, MA, USA) were injected with five 
million OPM-1 myeloma cells with isotype or AIN 457 ((10µg/ml)by sc route with 
approvals by the Institutional Animal Care and Use Committee (IACUC) (VA Boston 
Healthcare System). Tumor volume was measured at indicated time intervals as described 
previously31. In another set of experiments SCID mice were treated with with weekly sc 
injections following MM cell-injections. In addition, Balb/C mice were injected with murine 
plasmacytoma cell-line (ATCC CCL167/MPC11) and treated with isotype control antibody 
or murine anti-IL-17A mAb (10µg/ml) for a week with sc injections and tumor volumes 
were measured.
SCIDhu human myeloma model
Human fetal bone grafts were subcutaneously implanted into SCID mice (SCID-hu), as 
previously described32. Four weeks following bone implantation, 2.5×106 INA-6 MM cells 
were injected directly into the human bone implant. One group was treated with isotype 
control antibody and another group of mice was treated weekly subcutaneously with 
AIN-457 (10µg/ml) for four consecutive weeks following first detection of tumor.. Tumor 
growth was evaluated by measuring serum level of soluble humans IL-6R with ELISA R & 
D Systems).
MicroCT analysis of bones
The bone damage caused by myeloma cells from these mice was assessed by micro-
computed tomography (microCT) analysis at the end of the study as described33.
Quantitative PCR and western blot analysis
Quantitative PCR was performed for IL-17A using RNA isolated from MM cell-lines and 
purified MM primary cells. Results are presented as relative expression value in comparison 
with GAPDH. Cell lysates were probed with anti-sera to IL-17A and GAPDH (Santa Cruz 
Biotech, Santa Cruz, CA, USA). Myeloma cell lines were stained with isotype control 
antibody or anti–IL-17A antibody and analyzed by confocal microscopy. One representative 
cell-line of 4 experiments is shown at 640 magnification4.
siRNA and shRNA transfections
MM cells (U266) were transfected with siRNA or sh RNA or respective controls (Santa 
Cruz Biotech) for IL-17A and cultured to measure viability, colony formation and IL-6 
levels with BMSC.
Statistical analysis
Statistical analyses were performed by student ‘t’ test. P < 0.05 was considered statistically 
significant.
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Results
Growth inhibitory activity of anti-IL-17A antibody on myeloma
As IL-17A promotes myeloma cell growth and survival4, we investigated the effects of 
human anti-IL-17A monoclonal antibody (AIN-457) in MM. As seen in Figure 1A, anti-
IL-17A mAb significantly inhibited MM cell proliferation measured by 3H-thymidine 
incorporation (−21.8±2.14%, p<0.05) compared with proliferation of MM cell-lines with 
isotype control antibody. The inhibitory effect of anti-IL-17A mAb on myeloma cell-growth 
(−16.2± 2.3, p<0.05) compared with cell-growth of MM cell-lines with isotype control 
antibody was also observed using MTT assay. (Figure 1 B). We observed that anti-IL-17A 
mAb significantly inhibited colony formation in methoCult colony assay (40±5, p<0.05, 
compared to isotype control antibody, 80±4) (N=3) and with primary MM cells (N=4) 
(31±5, p<0.05, compared to isotype control, 84±7) (Figure 1C and D). These results suggest 
that anti-IL-17A mAb significantly inhibits growth of MM cell-lines and primary cells in 
vitro. We also observed anti-IL-6 antibody in the presence of IL-17A significantly reduced 
growth and proliferation induced by IL-17A in co-culture with BMSC, however, it did not 
take to control level in both thymidine incorporation (Figure 1E) and in MTT assays (Figure 
1F). On the other hand, adding IL-6 in the presence of anti-IL-17A antibody slightly 
increased growth and proliferation of myeloma cells in co-culture with BMSC and it did not 
restore the growth and proliferation of MM cells to the control level.
Down regulation of BMSC-mediated MM cell-growth by anti-IL-17A antibody via blockade 
of IL-6 production
We evaluated the influence of anti-IL-17A mAb on BMSC-mediated MM cell-growth. As 
seen in Figure 2A, anti-IL-17A mAb significantly inhibited MM cell-proliferation 
(−22.7±2.9%, p<0.05) in presence of BMSC compared with MM cell-proliferation in 
presence of BMSC with isotype control antibody in co-culture assays as measured by 3H-
thymidine incorporation.
It is well established that IL-6 produced by MM-BMSC interaction mediates MM cell 
growth. So we further investigated whether IL-17A affects IL-6 production by BMSC alone 
or in co-culture assays and whether anti-IL-17A mAb mediates part of its activity via its 
effect on IL-6 produced by BMSC. We evaluated the effect of the number of cytokines 
associated with Th17 pro-inflammatory pathway (IL-21, IL-22, IL-23, IL-27 and TGF-β) on 
IL-6 production by BMSCs. As seen in Figure 2B, only IL-17A, in addition to LPS used as a 
positive control, was able to induce significant increase in IL-6 production by BMSC 
compared with endogenous or base-line IL-6 production by BMSC without LPS. We further 
evaluated the influence of anti-IL-17A mAb on IL-17A-induced IL-6 production by BMSC 
alone or in co-culture systems. As seen in Figure 2C, IL-17A was able to significantly 
increase IL-6 production by BMSC alone (360±37% increase compared to endogenous IL-6 
production by BMSC alone, p<0.05, in the left side of Figure 2C) and in co-culture with 
MM cells (514±76% increased compared to endogenous levels of IL-6 by BMSC alone and 
co-culture controls, p<0.05, in the right of Figure 2C). While anti-IL-17A mAb was able to 
significantly decrease (p<0.05) the IL-6 production by BMSC (77±4.5%, in the left side of 
Figure 2C) compared with endogenous levels of IL-6 by BMSC alone with isotype control 
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antibody and in co-culture system (107±9% in the right of Figure 2C) compared with 
endogenous levels of IL-6 in co-cultures with isotype control antibody (212±32%). In 
addition, when we used anti-IL-17A mAb + IL-17A in combinational studies, we observed 
that anti-IL-17A mAb was also able to reduce significantly IL-6 production in presence of 
IL-17A, (142±18% compared with IL-6 production by BMSC with IL-17A with isotype 
control antibody, 360±37%, in the left side of Figure 2C) and in co-culture (245±33% 
compared with IL-6 production in co-culture with IL-17A with isotype control antibody, 
514±76%, in the right of Figure 2C). We next evaluated the effect of anti-IL-17A mAb on 
the ability of myeloma cells to bind to BMSC using established adhesion assay. Calcein- 
labeled MM cells were co-cultured with BMSC for 4 hours and adhesion was measured as 
described in methods. Presence of anti-IL-17A mAb (N=3) significantly reduced (27±3.8%, 
p<0.05) MM cell-BMSC adhesion as compared to adhesion of MM cells to BMSC in the 
presence of isotype control antibody as measured by the absorbance using a fluorescence 
plate reader (Figure 2D). Finally, when we inject MM cells ex-vivo into human fetal bone 
chips IL-6 production was significantly reduced in presence of anti-IL-17A mAb, compared 
to IL-6 production in the presence of isotype control antibody after 48 hours (Figure 2E). 
Analysis of these bone chips by immune-histochemistry using anti-CD138 mAb showed 
significant reduction of CD138+ expression (dim or low) of plasma cells by anti-IL-17A 
mAb compared to CD138+ expression (bright or high) in the presence of isotype control 
antibody (Figure 2F). When myeloma cells were co-cultured with BMSC in presence of 
IL-17A with or without different cell-signaling inhibitors (JAK2, STAT3, JNK, MEK, NFkB 
and PI3 inhibitors), IL-6 production was significantly inhibited by all of these signaling 
pathway inhibitors except STAT3.
Down-regulation of osteoclast development in vitro by ant-IL-17A mAb
IL-17 has also been shown to play a critical role in the genesis of bone disease in myeloma 
by mediating osteoclast formation and activation23–24. Normal BMMC were cultured for 
three weeks in osteoclast-supporting medium with isotype control antibody or anti-IL-17A 
mAb, and stained for TRAP+ multi-nucleated osteoclast cells. TRAP-positive stained cells 
containing 5 or more nuclei/cell were enumerated with the aid of microscope and image J 
software. A representative image was depicted (Figure 3A) showing pink cells as 
TRAP+multi-nucleated osteoclasts in positive control in the presence of isotype control 
antibody as compared with anti-IL-17A mAb treated group showing osteoblast-looking 
growth patterns. As seen in Figure 3B, the osteoclast cell number was significantly 
decreased (by 42%) by anti-IL-17A mAb treatment (23±4) compared with the positive 
control with isotype control antibody (55±4) (p<0.05) in osteoclast-supporting media.
Inhibition of human myeloma cell-growth in vivo by systemic administration of anti-IL-17A 
mAb in murine models of human myeloma
Next, we evaluated the efficacy of anti-IL-17A mAb in animal models using two different 
animal models of human myeloma. Initially in xenograft model, SCID mice were injected 
with myeloma cells along with isotype control antibody or AIN 457 subcutaneously. Tumor 
volumes were measured at 24 and 30 day time intervals after MM cell injections. As seen in 
Figure 4A in a representative of two experiments, the presence of anti-IL-17A mAb 
significantly reduced tumor size (37% inhibition at 24 days and 47% inhibition at 30 days, 
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p<0.05) compared to the tumor volumes in the presence of isotype control antibody 
treatment group at both time points evaluated, as seen in Figure 4A. The reduction in tumor 
volumes by anti-IL-17A mAb may be due to both either inhibiting tumor growth and/or 
tumor engraftment in this animal model. In another set of experiments, SCID mice were 
treated with weekly sc injections following MM cell-injections. Even though we observed 
that anti-IL-17A mAb reduced (by 35% at 24 days after MM cell injection) myeloma growth 
in this SCID xenograft mice study and the difference in tumor volumes between isotype 
control antibody (2007±584mm3) and treated groups (1299±282mm3) is not statistically 
significant, as seen in Figure 4B. To evaluate the efficacy of anti-IL-17A mAb in immune 
competent mice, Balb/C mice were injected with murine plasmacytoma cell-line (ATCC 
CCL167/MPC11) and treated with isotype control antibody (N=13) or murine anti-IL-17A 
mAb (N=20) (10µg per mice) for a week and their tumor volumes were measured. However, 
we observed that anti-IL-17A mAb reduced (by 32%) myeloma growth in this immune 
competent mice study and the difference in tumor volumes between the isotype control 
antibody (1217±207mm3) and the treated groups (827±113mm3) was not statistically 
significant by the student “t” test evaluation.
Next, we evaluated the efficacy of anti-IL-17A mAb in the SCIDhu animal model of human 
myeloma. This model represents human myeloma development in the presence of BMSC. 
SCID mice were transplanted with human fetal bone-chips, and after four weeks, myeloma 
cells were injected into the fetal bones. Following the first detection of the tumor, one group 
of mice was treated with human IgG isotype control antibody and the other group of mice 
was treated with anti-IL-17A mAb (10µg/mouse/injection) subcutaneously with weekly 
injections, for four weeks. Serum samples were collected weekly and level of human soluble 
IL-6R was measured by standard commercially available ELISA as a measure of tumor 
growth29. As seen in Figure 5A a representative of two experiments, anti-IL-17 mAb 
significantly inhibited (by 5 times-lower) tumor growth (5.9±2.8 ng/ml of sIL-6R) compared 
to isotype control antibody (30.9±10.5 ng/ml of sIL-6R) mice (p<0.05). This SCIDhu human 
myeloma model is very similar to human myeloma conditions with its BM 
microenvironmental settings. The efficacy of this anti-IL-17A mAb in this SCIDhu human 
myeloma against myeloma cells is excellent by inhibiting 81% of myeloma cells ability to 
produce soluble IL-6 receptor while they are growing. We have used this SCIDhu human 
myeloma model for evaluating pre-clinical efficacy of number of agents including 
chemotherapeutic agents and antibodies. In our pre-clinical efficacy evaluation studies using 
the SCIDhu human myeloma model over the past decade, the anti-IL-17A mAb was shown 
to be the best and have the highest efficacy against myeloma. As we are seeing obvious 
statistically significant differences between isotype control antibody and anti-IL-17A mAb 
treated mice, and as results are confirmed in 2 different animal models, we believe it 
provides adequate evidence for clinical evaluation of anti-IL-17 mAb in MM. Additionally, 
anti-IL-17A mAb was also able to prevent the bone resorption caused by MM cells. At the 
termination of the experiment, microCT studies of the human bones harvested from animals 
reveals protection by anti-IL17A from the bone resorption associated with myeloma tumor 
growth in the presence isotype control antibody as seen in Figure 5B. The measurements of 
bone resorption showed that the prevention of resorption is significantly higher by the anti-
Prabhala et al. Page 7
Leukemia. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
IL-17A mAb treatment group compared with isotype control antibody treatment group 
(Figure 5C).
Expression of IL-17A in myeloma cells and functional consequences by knockdown with 
siRNA and shRNA on growth and survival of myeloma cells
To validate expression of IL-17A by MM cells, we performed quantitative RT-PCR in both 
MM cell lines and CD138+ primary MM cells from patients. We observed the expression of 
IL-17A in majority of MM cell-lines as well as primary MM cells (Figure 6A/B). The 
IL-17A expression was higher in 5 out 7 tested MM cell-lines compared with the expression 
of IL-17A in PBMC collected from healthy donor. Expression of IL-17A protein was 
confirmed by western blot in all MM cell-lines and 7 out of 9 purified primary MM cells 
(Figure 6C/D). The IL-17A protein levels were lower in CD138+ primary MM cells 
compared with cell-lines and Th17 cells as a positive control. Normal CD138+ cells 
collected from healthy donors have shown no IL-17A protein. Finally, we also show intra-
cellular IL-17A protein in MM cells by confocal microscopy (Figure 6E).
In order to investigate the functional consequences of IL-17A expression by MM cell-line 
(U266), we evaluated impact of IL-17A knock-down on MM cell growth and colony 
formation. IL-17A Knock-down, using IL-17-specific siRNA (Figure 7A) inhibited MM 
cell-growth as well as colony formation in MethoCult agar plates (Figure 7C). We also 
confirmed these results using IL-17A-specifc shRNA (Figure 7B). IL-17A induces IL-6 
production by stromal cells in various tissues20 and we have previously reported that 
IL-17A elevates IL-6 production by BMSC. So, we evaluated impact of IL-17A knock-down 
on IL-6 production by BMSC. IL-6 production in MM/BMSC co-culture was significantly 
reduced following IL-17A knock-down in MM cells (Figure 7D). These results show that 
IL-17A expressed by MM cells have impact on growth of MM cell as well as on the 
microenvironment.
Discussion
IL-17A, a key pro-inflammatory cytokine, is predominantly produced by T helper cells in 
addition to other immune cell-types including γδ and CD8+ T cells, and NKT cells34. 
Although it provides protective effects against intra-cellular bacterial/viral, fungal and 
parasitic infectious agents9, it plays a deleterious role in immune-pathology of 
autoimmune13 and inflammatory diseases including asthma35, in addition to cancer26–28,36. 
The demonstration of elevated levels of Th17 cells and serum IL-17A in myeloma may help 
explain the reported higher incidence of MM in patients with autoimmune diseases. Our 
recent data also suggests elevated levels of other Th17-associated pro-inflammatory 
cytokines including IL-21, IL-22 and IL-23 in both peripheral blood and BM sera samples 
from MM compared to control samples4. Moreover, IL-17A induces MM cell proliferation 
with or without BMSC and increases MM cell adhesion to BMSC4. The presence and 
requirement of IL-17RA on MM cells further supports the role of IL-17A in MM cell 
growth and survival, and confirms it as a novel therapeutic target. IL-17A effects on 
immuno-paresis in myeloma with suppressed Th1 responses in the presence of IL-224 and 
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its activating effects on osteoclast with consequent effect on bone disease in myeloma23–24, 
provide added rationale to the target IL-17A in MM.
Here, we have evaluated the preclinical efficacy of human anti-IL-17A mAb on MM in vitro 
and in vivo. We observe that anti-IL-17A mAb significantly inhibit the growth of MM cell 
lines as well as primary cells and are able to overcome protective effects of BMSCs. The 
observed effects of anti-IL-17A mAb on MM cells in culture as well as in colony assay is 
intriguing and raises the question about the source of IL-17A in this system. In MM, we and 
others, have shown that IL-17A supports the MM cell growth and survival4,17,23. Further 
disease progression was observed with increased IL-17A serum levels18–22. Reduction of 
IL-17 after bisphosphonate treatment has also been reported25. These studies point out a 
significant role for IL-17A modulation in myeloma therapeutics.
It has been well established that IL-17A may cause its deleterious pathological effects 
through the increased production of IL-6, particularly in rheumatoid arthritis37–38. We have 
shown for the first time that MM IL-17A induces IL-6 production by BMSC alone and in 
co-culture with MM cells. In addition, these results indicate that the other pro-inflammatory 
cytokines-associated with Th17 cells including IL-21, IL-22, IL-23 and IL-27 do not induce 
the IL-6 production by BMSC. We observed that anti-IL-17A mAb was able to significantly 
down-regulate MM cell-BMSC adhesion and IL-6 production. These results were consistent 
with previous observations that IL-6 production was elevated in stroma in tissues38. In order 
to show the importance of IL-17A in the production of IL-6 in co-culture settings, 
neutralization studies showed that anti-IL-6 antibody did not completely inhibit IL-17A 
effects and adding IL-6 did not restore AIN 457 inhibition on the growth and proliferation of 
MM cells. These studies taken together indicate that IL-17A-mediated growth and 
proliferation MM cells are in part mediated by IL-6 and in part mediated other factors. 
IL-17A induces number of pro-inflammatory factors in addition to IL-638.
Since elevated levels of IL-6 and MM-BMSC interaction are involved in bone damaging 
effects during the progression of myeloma disease, inhibition of effects of IL-17A on IL-6 
production can help improve bone disease in MM. IL-17A increases osteoclast-
differentiation and thereby is partly responsible for associated bone damages observed in 
rheumatoid arthritis39–40and IL-17 has also been shown to play a critical role in the genesis 
of bone disease in myeloma by mediating osteoclast formation and activation23–24. 
Therefore, we evaluated and observed significant inhibition of TRAP+ multinucleated 
osteoclast cell–differentiation by anti-IL-17A mAb. These results are in agreement with the 
recent report showing that the elevated levels of IL-17A and IL-1β in the BM plasma 
correlate with lytic bone disease in MM patients23. We have also observed anti-MM activity 
of anti-IL-17 mAb in two murine models of myeloma; the subcutaneous MM xenograft 
model, where a pre-treatment with anti-IL-17 mAb led to significant reduction in tumor 
volume, and more importantly in the SCIDhu model of human MM cells. In the second 
model the results are especially interesting as we have a human micro-environment in this 
setting providing some of the cellular components of the human BM micro-environment. 
Number of studies has described increased frequency of Th17 cells in other human 
malignancies including, ovarian, prostate, renal, and pancreatic carcinomas26–28. Moreover, 
IL-17 has also been linked to poor survival in number of other cancers, including AML, 
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breast, colorectal, liver, lung, and melanoma40–42. We have showed that myeloma cells 
express IL-17 by number ways including western blot and quantitative PCR assays in 
addition to confocal microscopy. In human studies, transduction of IL-17 in 3 different non-
small cell lung cancer cell lines, also expressing IL-17 receptors, led to significant increase 
in tumor growth in SCID model compared to control cells suggesting possible role of 
autocrine loop in these cancer cells43. Similar in vitro and in vivo results have been also 
reported in cervical cancer suggesting role for IL-17A expression by tumor cells44. 
Conversely, regardless of the source of IL-17, IL-17 receptor deficiency has been reported to 
show reduced number of invasive prostate adenocarcinoma with lower rate of cellular 
proliferation suggesting that IL-17-mediated signaling promotes tumor growth45. These 
studies collectively suggest that expression of IL-17A and its receptors by tumor cells may 
affect their growth. In our setting it appears that MM cells inherently express both IL-17R as 
we have previously reported4, and also IL-17A as reported here. We have also observed the 
functional impact by IL-17A knock-down on tumor cell growth as well as on supporting BM 
microenvironment. The impact of IL-17A produced by MM cells on BMSC is also very 
intriguing. Induction of IL-6 in BMSCs, by MM cell-derived IL-17A, may suggest in part a 
unique pathway for IL-6 production. A report of IL-17 production by MM cell may provide 
an explanation of the source IL-17 in this system46. Moreover, we have shown earlier4, using 
various methods, that MM cells do express IL-17 receptors, suggesting a possible autocrine 
loop is in play in MM using IL-17A and its receptor pathway. IL-17R-mediated pathways 
are very complex due to the presence of five different IL-17R and warrant further 
confirmative studies. The efficacy of neutralization of IL-17A in a variety of disease states, 
including asthma and lung inflammatory diseases47, rheumatoid arthritis48–49, and multiple 
sclerosis50 where IL-17A participates in the development and/or patho-physiology disease, 
has been shown in addition to other cytokine targets in Th17 pathway51–52.
IL-17A is present in synovial fluids in RA and it participates in bone erosion53. Efficacy of 
anti-IL-17A mAb has been confirmed in three proof-of-concept trials recently; clinically 
significant improvements were observed in patients with psoriasis, rheumatoid arthritis and 
uveitis, where IL-17A has been implicated in the disease process without major adverse 
effects54. The second trial evaluating patients with rheumatoid arthritis where anti-IL-17A 
mAb, ixekizumab (LY2439821), showed improved signs and symptoms of RA without 
strong adverse effects55 against psoriasis56. The third study is a phase 2, randomized, 
double-blind, placebo-controlled dose-ranging study of brodalumab (AMG 827), a human 
anti-IL17-receptor monoclonal antibody for psoriasis57.
In summary, we show that the anti-IL-17A mAb (AIN 457) is able to inhibit MM growth 
and survival both in vitro and in vivo studies by blocking in part, positive autocrine feedback 
loop in addition to inhibiting IL-6 production by BMSC ; it improves bone defects in MM 
and has the potential to improve immune function in MM. These results confirm the 
rationale for clinical evaluation of anti-IL-17 mAb in MM.
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Figure 1b
Figure 1. Inhibitory activity of anti-IL-17A antibody on myeloma cell proliferation
(A) Myeloma cell lines alone (N=8) were incubated with isotype control antibody or anti-
IL-17A mAb to measure proliferation by 3H-thymidine incorporation after 3 days. Data is 
presented as percentage inhibition in proliferation in presence of anti-IL-17A mAb 
compared with isotype control antibody and showed as mean ± SEM. (B) Myeloma cell 
lines alone (N=5) were incubated with isotype control antibody or anti-IL-17A mAb to 
measure metabolic activity by MTT assay after 3 days. Data is presented as percentage 
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inhibition in proliferation in presence of anti-IL-17A mAb compared with isotype control 
antibody and showed as mean ± SEM. (C) Myeloma cell lines (U266) were cultured in 
methocult agar plates in the presence of isotype control antibody or anti-IL-17A mAb. 
Representative photomicrograph and results (N=3) are presented. Photographs were 
obtained using a Nikon TE200 microscope (40× objective) with attached camera (Nikon) at 
room temperature (total magnification 200) and analyzed with Metafluor software 
(Molecular Devices). The number of colonies were counted in unit area and presented as 
mean ± SEM. (D) Primary MM cells (N=4) were cultured in methocult agar plates in the 
presence of isotype control antibody or anti-IL-17A mAb. The number of colonies were 
counted in unit area and presented as mean ± SEM. *P <0.05. Myeloma cells (U266) was 
cocultured with BMSC for three days in the presence of isotype, IL-17A with or without 
anti-IL-6 (10 µg/ml) antibody, and anti-IL-17A antibody with or without IL-6 (10ng/ml) and 
proliferation was measured by thymidine incorporation (Figure E) and MTT (Figure F) 
assays. Data is presented as percentage control co-culture proliferation and showed as mean 
± SEM.
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Figure 2b
Figure 2. Down regulation of BMSC-mediated MM cell-growth by anti-IL-17A antibody via 
blockade of IL-6 production
(A) MM cell lines (N=7) were cultured with BMSCs in the presence of isotype control 
antibody or anti-IL-17A mAb and proliferation measured by 3H-thymidine incorporation 
after 3 days and presented as percentage of inhibition in proliferation with isotype control 
antibody. (B) BMSC was cultured for three days in the presence or absence of IL-17A 
(100ng/ml), IL-21, IL-22, IL-23, IL-27 and LPS at 10ng/ml concentration. IL-6 production 
was measured by standard ELISA (R&D Systems, Minneapolis, MN). Bar graph represents 
mean ± SEM of the data (N=4) calculated as percent of increase or decrease in IL-6 levels in 
culture supernatants compared to IL-6 levels (as endogenous IL-6 production) obtained from 
BMSC alone without any stimulation. (C) BMSC in the presence (right or absence (left) of 
MM cell-lines was cultured with isotype control antibody, IL-17A, or anti-IL-17A mAb or 
in combination with IL-17A + anti-IL-17A mAb and IL-6 levels were measured in culture 
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supernatants by ELISA. Bar graph represents mean ± SEM of the data calculated as percent 
of increase or decrease in IL-6 levels in culture supernatants compared to IL-6 levels (as 
endogenous IL-6 production) obtained from BMSC alone with isotype control antibody 
without any stimulation. (D) Serum-starved MM cells were labeled with calcein AM, 
washed, and added to BMSC-coated plates in the presence of isotype control antibody or 
anti-IL-17A mAb for 4 hours and non-adherent cells were removed by washing. Adhesion 
was measured by measuring the absorbance using 492/520 nm filter set with a fluorescence 
plate reader. Results represent mean ± SEM of 3 independent experiments performed in 
triplicate. The absorbance values obtained with isotype control antibody was considered as 
100% and percentage of inhibition was calculated for anti-IL-17A treatment. (E) The fetal 
bone chips with MM cells were incubated in the presence of isotype control antibody or 
anti-IL-17A mAb for 2 days for ex-vivo for the evaluation of IL-6 production that is 
measured by ELISA (R & D Systems). Bar graph represents mean ± SEM of the data 
calculated as percent of IL-6 levels (as endogenous IL-6 production) in culture supernatants 
from BMSC alone with isotype control antibody. (F) The immunohistochemical analysis of 
bones was performed by staining them with anti-CD138 antibody. Arrows indicates presence 
bright CD138+cells. (G) Myeloma cells were co-cultured with BMSC in the presence of 
IL-17A with or without cell-signaling inhibitors (JAK2, STAT3, JNK, MEK, NFkB and PI3 
inhibitors) and IL-6 production was measured with standard ELISA. *P <0.05.
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Figure 3. Reduced osteoclast cell numbers by the antibody
Normal BM cells were cultured for three weeks in osteoclast supporting-medium (consisting 
25ng/ml of macrophage colony-stimulating factor and 25 ng/ml of receptor activator of 
nuclear factor kappa-B ligand) with isotype control antibody (as positive control) or anti-
IL-17A antibody and the tartrate-resistant acid phosphatage (TRAP+) multinucleated 
osteoclast cells were stained and cell-numbers were counted. Cells were cultured without 
osteoclast-supporting-medium as negative control. Images were obtained at 10 
magnifications with microscope (Eclipse TS100, Nikon instruments, Melville, NY, USA) 
with spot insight camera. TRAP-positive cells containing 5 or more nuclei/cell were 
enumerated using image J 1.45 software (NIH, Bethesda, MD, USA). A representative 
image was depicted (Figure A) and composite results from three experiments were shown in 
bar graph Figure B). Star indicates statistical signifies (p<0.05). There were no significant 
differences observed among three groups in cell-viability measured with alamor blue 
staining.
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Figure 4. Effect of AIN-457 humanized antibody on myeloma growth using three mouse models 
without tumor microenvironment
(A) SCID mice were injected with myeloma cells by sc route. Mice were injected in 2 
groups (N=3). One group was injected with myeloma cells with isotype control antibody; 
and second of mice injected with MM cells in anti-IL-17A mAb (10µg/ml). Tumor volume 
was measured at indicated time intervals from the MM cell-injections. Representative of two 
experiments is shown (p<0.05). (B) SCID mice were treated with isotype control antibody or 
anti-IL-17A mAb (10µg/ml) with weekly sc injections following subcutaneous MM cell-
injections (N=4). Tumor volumes (mm3) were measured at indicated time intervals. 
Representative of two experiments is shown. (C) Balb/C mice were injected with murine 
plasmacytoma cell-line and treated with isotype control antibody or murine anti-IL-17A 
mAb (10µg/ml) for a week with sc injections and tumor volumes were measured.
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Figure 5. Inhibition of tumor growth and prevention of bone resorption by AIN-457, IL-17A 
antibody in SCID human myeloma model
A) SCID mice were transplanted with human fetal bones, and after four weeks, myeloma 
cells were injected into the bones. One group was treated with vehicle with isotype control 
antibody and another group of mice were treated subcutaneously with AIN-457 (10µg/ml-/
mouse/injection) for four weeks following first detection of tumor by measuring human 
soluble IL-6R in the serum. Serum samples were collected weekly and level of humans 
IL-6R was measured by ELISA. Baseline values before treatment were not significantly 
different among groups. Representative of two experiments is shown (p<0.05). B) 
Treatment with anti IL-17A protects implanted bones from osteolysis. At the 
termination of the experiment, implanted human bones were excised and imaged by 
microcomputed tomography (microCT). Shown are the three-dimensional reconstructions of 
the bones and sections sliced longitudinally through the midpoint of each specimen injected 
with MM cells followed by treatment of the animal with either isotype control antibody 
(excessive bone resorption is seen) or anti IL-17A (no bone resorption is observed, 
trabecular bone is intact). The areas of increased osteoclastic bone resorption in the isotype 
control antibody-treated sample are indicated by arrowheads. Scale bar equals 1 mm3. Anti-
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IL-17A antibody reduced the bone resorption caused by myeloma cells. C) Significant 
differences in the measurements of bone resorption following anti-IL-17A mAb treatment.
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Figure 6. Analysis of IL-17A expression in myeloma cells
The MM patient samples were collected after informed consent in accordance with the 
Declaration of Helsinki and approved by the institutional review board (IRB) from Dana-
Farber Cancer Institute. Healthy donor bone marrow samples were obtained from AllCells 
(Emeryville, CA). MM primary cells were purified as described earlier5. RNA was isolated 
from MM cell-lines (A) and purified MM primary cells (B). Quantitative PCR was 
performed for IL-17A using 7900HT from Applied Biosystems. Representative 
experimental results from three different experiments were presented as relative expression 
value in comparison with GAPDH. For immuno-blot experiments, total cell lysates were 
prepared from MM cell-lines (C) and purified CD138+ MM primary cells (D), and separated 
by electrophoresis on 5% to 20% polyacrylamide gradient gels. Samples were probed with 
anti-sera to IL-17A and GAPDH as indicated. Representative immunoblot of three different 
experiments was shown. Myeloma cell lines were stained with isotype control antibody or 
anti–IL-17A antibody and analyzed by confocal microscopy. One representative cell line of 
4 experiments was shown at 640 magnifications (E).
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Figure 7. IL-17A knockdown decreases myeloma cell-number and their ability to produce IL-6 
in a co-culture with bone-marrow stromal cells
Myeloma cell-line (RPMI 8226) cells were used to transduce human IL-17A siRNA 
according to manufactures recommendations to determine the influence on myeloma cell-
proliferation and their ability to produce IL-6 when co-cultured with bone-marrow stromal 
cells. Cell lysates were analyzed using immuno-blots to assess decrease in intra-cellular 
protein expression of IL-17A (A). Cell-proliferation was analyzed by counting live cells 
following transfection. Representative study results of three different experiments were 
shown. MM cell-line (U266) was used to transduce human IL-17A shRNA according to 
manufactures recommendations to determine the influence on myeloma cell-expression and 
–proliferation (B). Representative study results of three different experiments were shown. 
Colony formation was evaluated using MethoCult agar plates following transfection with 
siRNA or shRNA (C). Representative study results of five different experiments were 
shown. IL-6 production was measured with standard ELISA following co-culturing 
myeloma cells with or without transfected MM cells with BMSC (D). Representative study 
results of three different experiments were shown.
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